Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe PainAccesswire • 01/31/24
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL MeetingAccesswire • 01/25/24
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPARAccesswire • 01/23/24
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023Accesswire • 12/19/23
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day PodcastAccesswire • 12/11/23
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note FinancingAccesswire • 11/29/23
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United StatesAccesswire • 11/28/23
Ensysce Biosciences Announces Enrollment Completion for PF614-201 Clinical StudyAccesswire • 11/16/23
Ensysce Biosciences Chief Medical Officer to Chair the 17th Annual Pain Therapeutics SummitAccesswire • 10/11/23
Ensysce Biosciences Announces Completion of Site Initiation Visit for PF614-201 Clinical StudyAccesswire • 09/26/23
Ensysce Biosciences to Host Research and Development FAQ Session Following PAINWeek Symposium on September 21, 2023Accesswire • 09/19/23
Ensysce Biosciences Completes Scale Up Manufacture of PF614 to Support Phase 3 StudiesAccesswire • 09/14/23
Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAccesswire • 09/05/23
Ensysce Biosciences to Present Clinical Dataset at Major PAINWeek Scientific SymposiumAccesswire • 08/14/23